Does the media refer more to IMRX or SERA?

In the previous week, Immuneering and Immuneering both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat Immuneering's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IFRX or SERA?

Sera Prognostics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 10,905.38 -$51.63M -$0.58 N/A Sera Prognostics $80K 996.11 -$31.93M -$0.67 N/A

Is IFRX or SERA more profitable?

InflaRx has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Sera Prognostics -47,475.72% -46.71% -34.06%

Does the media refer more to IFRX or SERA?

In the previous week, InflaRx had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Sera Prognostics. InflaRx's average media sentiment score of 1.61 beat Sera Prognostics' score of 0.59 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SERA or EBS?

In the previous week, Emergent Biosolutions had 10 more articles in the media than Sera Prognostics. MarketBeat recorded 11 mentions for Emergent Biosolutions and 1 mentions for Sera Prognostics. Emergent Biosolutions' average media sentiment score of 0.63 beat Sera Prognostics' score of 0.59 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SERA or MYGN?

In the previous week, Myriad Genetics had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Myriad Genetics and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat Myriad Genetics' score of 0.47 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SERA or IRD more profitable?

Opus Genetics has a net margin of -1,091.82% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -47,475.72% -46.71% -34.06% Opus Genetics -1,091.82% -338.88% -150.13%

Does the media refer more to SERA or IRD?

In the previous week, Opus Genetics had 6 more articles in the media than Sera Prognostics. MarketBeat recorded 7 mentions for Opus Genetics and 1 mentions for Sera Prognostics. Opus Genetics' average media sentiment score of 0.68 beat Sera Prognostics' score of 0.59 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sera Prognostics (SERA) Competitors

$2.02 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

SERA vs. IMRX, IFRX, EBS, MYGN, and IRD

Should you buy Sera Prognostics stock or one of its competitors? Sera Prognostics's main competitors and comparable companies include Immuneering (IMRX), InflaRx (IFRX), Emergent Biosolutions (EBS), Myriad Genetics (MYGN), and Opus Genetics (IRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sera Prognostics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Sera Prognostics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A

Immuneering currently has a consensus target price of $17.50, indicating a potential upside of 263.07%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 172.28%. Given Immuneering's stronger consensus rating and higher probable upside, equities analysts clearly believe Immuneering is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Immuneering has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, Immuneering and Immuneering both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat Immuneering's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Immuneering's return on equity of -27.15% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 14.9% of Immuneering shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Immuneering beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Sera Prognostics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	10,905.38	-$51.63M	-$0.58	N/A
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A

In the previous week, InflaRx had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Sera Prognostics. InflaRx's average media sentiment score of 1.61 beat Sera Prognostics' score of 0.59 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InflaRx currently has a consensus price target of $7.33, suggesting a potential upside of 230.33%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 172.28%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

InflaRx has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

InflaRx has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Summary

InflaRx beats Sera Prognostics on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Emergent Biosolutions?

Sera Prognostics (NASDAQ:SERA) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Emergent Biosolutions has a net margin of -22.95% compared to Sera Prognostics' net margin of -47,475.72%. Emergent Biosolutions' return on equity of 16.35% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 172.28%. Emergent Biosolutions has a consensus target price of $10.00, suggesting a potential upside of 61.03%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sera Prognostics is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Emergent Biosolutions had 10 more articles in the media than Sera Prognostics. MarketBeat recorded 11 mentions for Emergent Biosolutions and 1 mentions for Sera Prognostics. Emergent Biosolutions' average media sentiment score of 0.63 beat Sera Prognostics' score of 0.59 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Emergent Biosolutions has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A
Emergent Biosolutions	$742.90M	0.43	$52.60M	-$3.55	N/A

Sera Prognostics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

Summary

Emergent Biosolutions beats Sera Prognostics on 11 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Myriad Genetics?

Sera Prognostics (NASDAQ:SERA) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 1.9% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Myriad Genetics has a net margin of -13.96% compared to Sera Prognostics' net margin of -47,475.72%. Myriad Genetics' return on equity of -16.09% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Sera Prognostics presently has a consensus price target of $5.50, suggesting a potential upside of 172.28%. Myriad Genetics has a consensus price target of $3.60, suggesting a potential upside of 12.85%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sera Prognostics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

Sera Prognostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Sera Prognostics has higher earnings, but lower revenue than Myriad Genetics. Sera Prognostics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A
Myriad Genetics	$824.50M	0.37	-$365.90M	-$1.19	N/A

In the previous week, Myriad Genetics had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Myriad Genetics and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat Myriad Genetics' score of 0.47 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sera Prognostics beats Myriad Genetics on 9 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Opus Genetics?

Sera Prognostics (NASDAQ:SERA) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

In the previous week, Opus Genetics had 6 more articles in the media than Sera Prognostics. MarketBeat recorded 7 mentions for Opus Genetics and 1 mentions for Sera Prognostics. Opus Genetics' average media sentiment score of 0.68 beat Sera Prognostics' score of 0.59 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sera Prognostics has higher earnings, but lower revenue than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	996.11	-$31.93M	-$0.67	N/A
Opus Genetics	$14.20M	27.18	-$49.59M	-$1.35	N/A

Sera Prognostics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Sera Prognostics currently has a consensus target price of $5.50, indicating a potential upside of 172.28%. Opus Genetics has a consensus target price of $10.69, indicating a potential upside of 128.96%. Given Sera Prognostics' higher probable upside, research analysts clearly believe Sera Prognostics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Opus Genetics has a net margin of -1,091.82% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Summary

Sera Prognostics beats Opus Genetics on 9 of the 16 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79.69M	$3.99B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-3.01	12.71	273.84	25.45
Price / Sales	996.11	1,344.26	625.55	100.83
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	1.04	16.39	11.01	6.39
Net Income	-$31.93M	-$22.85M	$3.49B	$358.69M
7 Day Performance	-4.72%	1.43%	1.63%	0.22%
1 Month Performance	-2.42%	6.00%	4.42%	-0.10%
1 Year Performance	-39.52%	49.38%	24.21%	14.04%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	2.5793 of 5 stars	$2.02 flat	$5.50 +172.3%	-39.5%	$79.69M	$80K	N/A	120
IMRX Immuneering	2.9695 of 5 stars	$4.85 -2.8%	$17.50 +260.8%	-12.5%	$322.84M	N/A	N/A	60
IFRX InflaRx	2.1222 of 5 stars	$2.16 +1.4%	$7.33 +239.5%	+34.5%	$313.89M	$30K	N/A	60
EBS Emergent Biosolutions	3.8622 of 5 stars	$6.17 +1.1%	$10.00 +62.1%	-17.9%	$312.77M	$742.90M	N/A	2,420	Positive News
MYGN Myriad Genetics	2.6887 of 5 stars	$3.18 -1.2%	$3.60 +13.2%	-51.7%	$307.99M	$824.50M	N/A	2,700	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. IMRX, IFRX, EBS, MYGN, and IRD

How does Sera Prognostics compare to Immuneering?

Summary

How does Sera Prognostics compare to InflaRx?

Summary

How does Sera Prognostics compare to Emergent Biosolutions?

Summary

How does Sera Prognostics compare to Myriad Genetics?

Summary

How does Sera Prognostics compare to Opus Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. IMRX, IFRX, EBS, MYGN, and IRD

How does Sera Prognostics compare to Immuneering?

Which has better earnings & valuation, IMRX or SERA?

Do analysts rate IMRX or SERA?

Which has more risk & volatility, IMRX or SERA?

Does the media refer more to IMRX or SERA?

Is IMRX or SERA more profitable?

Do institutionals & insiders have more ownership in IMRX or SERA?

Summary

How does Sera Prognostics compare to InflaRx?

Which has higher valuation and earnings, IFRX or SERA?

Does the media refer more to IFRX or SERA?

Do institutionals and insiders have more ownership in IFRX or SERA?

Do analysts prefer IFRX or SERA?

Which has more volatility & risk, IFRX or SERA?

Is IFRX or SERA more profitable?

Summary

How does Sera Prognostics compare to Emergent Biosolutions?

Is SERA or EBS more profitable?

Do analysts recommend SERA or EBS?

Do insiders and institutionals believe in SERA or EBS?

Does the media prefer SERA or EBS?

Which has higher earnings and valuation, SERA or EBS?

Which has more volatility and risk, SERA or EBS?

Summary

How does Sera Prognostics compare to Myriad Genetics?

Do insiders & institutionals believe in SERA or MYGN?

Is SERA or MYGN more profitable?

Do analysts recommend SERA or MYGN?

Which has more risk and volatility, SERA or MYGN?

Which has higher earnings & valuation, SERA or MYGN?

Does the media prefer SERA or MYGN?

Summary

How does Sera Prognostics compare to Opus Genetics?

Does the media refer more to SERA or IRD?

Do institutionals & insiders have more ownership in SERA or IRD?

Which has higher earnings and valuation, SERA or IRD?

Which has more risk and volatility, SERA or IRD?

Do analysts rate SERA or IRD?

Is SERA or IRD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools